(Q53586091)

English

Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.

scientific article published on 7 March 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

C S Higano

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

J Berlin

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

M Gordon

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

P LoRusso

4

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

S Tang

5

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

A Dontabhaktuni

6

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

J D Schwartz

7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

J Cosaert

8

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

J M Mehnert

9

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

publication date

7 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

33

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

450-462

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

https://scigraph.springernature.com/pub.10.1007/s10637-015-0217-7

0 references

The role of the IGF system in cancer: from basic to clinical studies and clinical applications

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Insulin-like growth factors and neoplasia.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Insulin-like growth factor-I receptor signaling blockade combined with radiation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Clinical factors predictive of long-term survival in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Insulin-like growth factor physiology and cancer risk

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Role of the insulin-like growth factor family in cancer development and progression

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

The effects of insulin-like growth factors on tumorigenesis and neoplastic growth

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Targeting insulin-like growth factor axis in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0217-7

21 January 2018

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25749986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25749986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25749986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25749986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).

1 reference

https://pubmed.ncbi.nlm.nih.gov/25749986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin-like growth factors and prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25749986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-015-0217-7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

release_zxgudl5wpfbzfpj3pxsi5llhvq

1 reference

https://api.fatcat.wiki/v0/release/zxgudl5wpfbzfpj3pxsi5llhvq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/25749986

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53586091&oldid=2144639417"